CN Patent

CN116723845A — 脱氧胞苷激酶抑制剂的结晶形式及其用途

Assigned to Tresilla Corp · Expires 2023-09-08 · 3y expired

What this patent protects

本文描述了作为脱氧胞苷激酶(dCK)抑制剂的化合物的结晶形式、制备此类结晶形式的方法、包含此类结晶形式的药物组合物和药物，以及使用此类结晶形式治疗将受益于对脱氧胞苷激酶(dCK)活性的调节的病状、疾病或病症的方法。

USPTO Abstract

本文描述了作为脱氧胞苷激酶(dCK)抑制剂的化合物的结晶形式、制备此类结晶形式的方法、包含此类结晶形式的药物组合物和药物，以及使用此类结晶形式治疗将受益于对脱氧胞苷激酶(dCK)活性的调节的病状、疾病或病症的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN116723845A
Jurisdiction
CN
Classification
—
Expires
2023-09-08
Drug substance claim
No
Drug product claim
No
Assignee
Tresilla Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.